Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Massachusetts General Hospital Cancer Center, Boston, MA, United States

Survival: 20.9 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Boston, MA
Hospital: Massachusetts General Hospital Cancer Center
Journal: Link
Date: 3/2012

This study involved women with HER2-negative locally advanced or metastatic breast cancer who were divided into two separate treatment groups. Group A had 115 patients with an average age of 55.1 years. Group B consisted of 114 patients with an average age of 54.4 years.

Patients in group A were treated with the biologic therapy agent sorafenib (an inhibitor of kinase proteins which are involved in cancer cell growth) and the chemotherapy agent capecitabine.

Patients in group B were treated with the chemotherapy agent capecitabine only.

The most severe treatment-related toxicity in group A was grade 4 neutropenia. Grade 3 hand-foot skin reaction, diarrhea, rash, and shortness of breath were also reported.

There were two treatment-related deaths due to unspecified causes in group B. Grade 4 mucosal inflammation, neutropenia, and shortness of breath were also reported.

The median overall survival for group A was 22.2 months. For group B, the median overall survival was 20.9 months.

Support: This study was partially supported by Onyx Pharmaceuticals and Bayer HealthCare Pharmaceuticals.

Correspondence: Dr. Jose Baselga; email:

E-mail to a Friend Email Physician More Information